Join WilmerHale Partners Barry Hurewitz and Barish Ozdamar for a comprehensive discussion covering NIH grants, FDA reviews and timelines, USPTO policies, intellectual property strategies, and licensing and collaborations. The event takes place at MBC BioLabs in San Francisco on March 18.
During the session, biotechnology and life science entrepreneurs will gain essential legal and strategic insights to adapt to shifting federal policies, discover innovative approaches to intellectual property, regulatory navigation, and licensing opportunities, and participate in a dynamic Q&A session to address your specific challenges.
MBC BioLabs is dedicated to helping biotech startups succeed. The incubator has helped launch and grow over 400 companies in our incubator since opening in October of 2013, and together, MBC companies have initiated 176 clinical trials, introduced 71 products to market, and collectively raised over $20 billion.
